Endometriosis, uterine fibroids; & premenopausal breast cancer (for 3.75 mg & 11.25 mg): hypoestrogenism-related symptoms: hair loss; arthralgia, myalgia, decreased bone mass; headache, dizziness & paresthesia; increased sweating; visual disturbance; decreased libido, emotional lability, depression & sleep disorders; decreased breast size, dry vagina/vaginitis; hot flushes, edema & wt changes. Anaphylactic reaction, rash & pruritus; nausea, vomiting & anorexia; abnormal liver function test values, usually transient; inj site reactions. Central precocious puberty: General allergic reactions (fever, rash, itching, anaphylactic reactions); emotional lability (eg, crying, irritability, impatience, anger, & aggression); headache, pituitary haemorrhage following initial administration in patients w/ pituitary adenoma, seizure; abdominal pain/cramps, nausea/vomiting; acne; vag bleeding, spotting, discharge; inj site reactions. Pituitary apoplexy; severe muscle pain. 3.75 mg & 11.25 mg: Prostate cancer: Bone pain, urinary tract obstruction & hematuria, weakness of lower extremity/paresthesia; anaphylactic reaction, rash & pruritus; hot flushes, diaphoresis, decreased libido, impotence, orchiatrophy & gynecomastia; nausea, vomiting, anorexia & diarrhea; decreased bone mass; abnormal liver function test values, usually transient; inj site reaction; headache, edema, dizziness & depression; QT prolongation.